Markman M - Search Results

1

Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.

Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Xu Y, et al. Among authors: markman m. JAMA. 1998 Aug 26;280(8):719-23. doi: 10.1001/jama.280.8.719. JAMA. 1998. PMID: 9728644

2

Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results.

Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Markman M, et al. Gynecol Oncol. 2000 May;77(2):321-2. doi: 10.1006/gyno.2000.5787. Gynecol Oncol. 2000. PMID: 10785487

3

Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.

Markman M, Kennedy A, Kim J. Markman M, et al. Gynecol Oncol. 2001 Dec;83(3):593-5. doi: 10.1006/gyno.2001.6432. Gynecol Oncol. 2001. PMID: 11733977

4

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.

Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Connelly E, et al. Among authors: markman m. Gynecol Oncol. 1996 Aug;62(2):166-8. doi: 10.1006/gyno.1996.0210. Gynecol Oncol. 1996. PMID: 8751544 Clinical Trial.

5

Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. Gynecol Oncol. 1997 Jun;65(3):434-6. doi: 10.1006/gyno.1997.4708. Gynecol Oncol. 1997. PMID: 9190971

6

Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-26-S15-29. Semin Oncol. 1997. PMID: 9346218

7

Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. J Cancer Res Clin Oncol. 1998;124(6):326-8. doi: 10.1007/s004320050177. J Cancer Res Clin Oncol. 1998. PMID: 9692840

8

Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. Gynecol Oncol. 1998 Oct;71(1):113-5. doi: 10.1006/gyno.1998.5168. Gynecol Oncol. 1998. PMID: 9784330 Clinical Trial.

9

Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. J Clin Oncol. 1998 Nov;16(11):3483-5. doi: 10.1200/JCO.1998.16.11.3483. J Clin Oncol. 1998. PMID: 9817264

10

Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.

Kennedy AW, Markman M, Webster KD, Kulp B, Peterson G, Rybicki LA, Belinson JL. Kennedy AW, et al. Among authors: markman m. Gynecol Oncol. 1998 Nov;71(2):288-90. doi: 10.1006/gyno.1998.5159. Gynecol Oncol. 1998. PMID: 9826473

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

815 results

Search Page

Filters